Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines
Conditions
Interventions
botulinum toxin
Placebo
Locations
10
United States
Ablon Skin Institute and Research Center
Manhattan Beach, California, United States
Dermatology Cosmetic Laser Medical Associates
San Diego, California, United States
Art of Skin, MD
Solana Beach, California, United States
Siperstein Dermatology Group, PLLC
Boynton Beach, Florida, United States
Facial Plastic Surgicenter, Ltd
Baltimore, Maryland, United States
The Center for Dermatology, Cosmetic & Laser Surgery
Mount Kisco, New York, United States
Start Date
February 10, 2020
Primary Completion Date
September 25, 2020
Completion Date
February 10, 2021
Last Updated
June 18, 2023
NCT04985916
NCT03911102
NCT04225260
NCT00884234
NCT02248844
NCT01124552
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions